A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Male or female participant aged 18 to 70 years(inclusive)at the time of informed consent.
• Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.
• ≥10% of BSA involvement at screening visit and randomization;
• Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization
Locations
Other Locations
China
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College
RECRUITING
Nanjing
Contact Information
Primary
Qianjin Lu, doctor
qianlu5860@pumcderm.cams.cn
+86 137 8709 7676
Time Frame
Start Date: 2024-12-31
Estimated Completion Date: 2025-11-30
Participants
Target number of participants: 140
Treatments
Experimental: Group 1: WD-890 Dose 1 QD and Placebo
Experimental: Group 2: WD-890 Dose 2 QD and Placebo
Experimental: Group 3: WD-890 Dose 3 QD and Placebo
Experimental: Group 4: Placebo
Related Therapeutic Areas
Sponsors
Leads: Zhejiang Wenda Pharma Technology LTD.